Sino Biological, Inc. (SHE: 301047) has announced plans to invest RMB 1 billion (USD 140 million) to create a one-stop biological reagent and technology service platform. The initiative also includes the development of a comprehensive bio-pharmaceutical innovation service park in the Beijing Economic-Technological Development Area. As of the announcement date, the Beijing-based company does not have in-house research and development (R&D) and manufacturing facilities.
Expansion in the US
On a related note, Sino Biological signed a lease with Hines last week to initiate the construction of its new Center for Bioprocessing (C4B) at the Levit Green facility in Houston, Texas, USA. This new site, the company’s first manufacturing base in the US, will focus on providing product manufacturing and Contract Development and Manufacturing Organization (CDMO) services.
Global Presence
Sino Biological, with subsidiaries in Suzhou and Taizhou (China), Frankfurt (Germany), Kawasaki (Japan), and Wayne, Pennsylvania (USA), is a global leader in the provision of mammalian cell-based recombinant proteins, antibodies, and related contract research services. The company’s latest investments highlight its commitment to expanding its global footprint and enhancing its service capabilities.-Fineline Info & Tech
